Scientists at Virginia Tech using CRISPR tools to improve memory in aged rats, illustrating potential for combating cognitive decline.
Scientists at Virginia Tech using CRISPR tools to improve memory in aged rats, illustrating potential for combating cognitive decline.
Àwòrán tí AI ṣe

Virginia Tech team improves memory in aged rats with targeted gene-editing

Àwòrán tí AI ṣe
Ti ṣayẹwo fun ododo

Scientists at Virginia Tech report that tuning specific molecular pathways with CRISPR-based tools improved memory in older rats across two peer‑reviewed studies, pointing to possible routes for tackling age‑related cognitive decline.

New research from Virginia Tech indicates that age‑related memory problems may be modifiable. In two studies led by associate professor Timothy Jarome and graduate researchers, the team used CRISPR tools to adjust molecular changes linked to memory decline in aging rats, a common model for human brain aging. (sciencedaily.com)

In the first study, published in Neuroscience on August 6, 2025, Jarome and doctoral student Yeeun Bae examined lysine‑63 (K63) polyubiquitination, a protein‑tagging process involved in neuron communication. They found that K63 tagging increases with age in the hippocampus, which supports memory formation and retrieval, but decreases in the amygdala, which is important for emotional memory. Using a CRISPR‑dCas13 RNA system, the researchers reduced K63 polyubiquitination in the hippocampus and further lowered it in the amygdala of aged rats, which improved contextual fear‑memory performance; these manipulations did not affect middle‑aged rats. “Adjusting this one molecular process helped improve memory,” Jarome said. (pubmed.ncbi.nlm.nih.gov)

A second paper, published October 1, 2025, in Brain Research Bulletin, targeted the imprinted memory‑supporting gene IGF2, whose activity declines in the aging hippocampus. The team showed that IGF2 is silenced with age via DNA methylation and used CRISPR‑dCas9 to increase 5‑hydroxymethylation at the Igf2 promoter—an epigenetic edit that reactivated the gene. Reactivating IGF2 improved memory and long‑term potentiation in aged, but not middle‑aged, rats. “We essentially turned the gene back on,” Jarome said. (pubmed.ncbi.nlm.nih.gov)

Taken together, the studies suggest that multiple molecular systems contribute to memory decline in aging and that precise interventions can restore performance in old animals. About one‑third of U.S. adults over 70 experience cognitive decline, underscoring the need for such mechanistic insights; the authors note that the work could help illuminate what goes wrong in dementia, though the findings are limited to animal models and far from clinical application. (pubmed.ncbi.nlm.nih.gov)

According to Virginia Tech, the projects were led by graduate researchers and carried out with collaborators at Rosalind Franklin University, Indiana University, and Penn State. The university also reports funding from the National Institutes of Health and the American Federation for Aging Research. NIH support is additionally documented in the journal records via listed grant numbers. (sciencedaily.com)

Awọn iroyin ti o ni ibatan

Split-scene illustration of UCSF mouse study: older mouse struggles in maze with poor hippocampal neural links due to FTL1; treated mouse excels with enhanced connections.
Àwòrán tí AI ṣe

UCSF study links iron-associated protein FTL1 to age-related memory decline in mice

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

Researchers at the University of California, San Francisco report that higher levels of the iron-associated protein FTL1 in the hippocampus of older mice are tied to weaker neural connections and worse performance on cognitive tests. In the experiments, reducing FTL1 in older mice was associated with increased neuronal connectivity and improved memory performance, findings published in Nature Aging.

Researchers at UCLA Health and UC San Francisco have identified a natural defense mechanism in brain cells that helps remove toxic tau protein, potentially explaining why some neurons resist Alzheimer's damage better than others. The study, published in Cell, used CRISPR screening on lab-grown human neurons to uncover this system. Findings suggest new therapeutic avenues for neurodegenerative diseases.

Ti AI ṣe iroyin

A team of researchers led by Professor Yan-Jiang Wang has published a review arguing that Alzheimer's disease requires integrated treatments targeting multiple factors, not single causes. New drugs like lecanemab and donanemab offer modest benefits by slowing decline, but fall short of reversal. The paper, in Science China Life Sciences, emphasizes genetics, aging, and systemic health alongside amyloid-beta and tau proteins.

Researchers at Texas Children’s Hospital’s Duncan Neurological Research Institute and Baylor College of Medicine report an experimental gene-targeting approach designed to increase levels of the MeCP2 protein disrupted in Rett syndrome. In mouse experiments and neurons derived from patient cells, the strategy boosted MeCP2 and partially restored cellular structure, electrical activity and gene-expression patterns, according to findings published in Science Translational Medicine.

Ti AI ṣe iroyin

Researchers at UCLA have identified a protein that slows muscle repair in aging but enhances cell survival in mice. Blocking the protein improved healing speed in older mice, though it reduced long-term stem cell resilience. The findings suggest aging involves survival strategies rather than mere decline.

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ